Navigation Links
Elusive gene mutations found for malignant brain tumor
Date:8/4/2011

DURHAM, N.C. -- A discovery by scientists at Duke University Medical Center and Johns Hopkins University could increase the chances for an effective combination of drug therapy to treat the second most common type of brain tumor.

For years scientists have been looking for the primary cancer genes involved in the development of oligodendrogliomas. Scientists knew the two chromosomes that held the probable mutations, but not the particular gene information.

Now scientists at Duke and Johns Hopkins have discovered the most likely genetic mutations that researchers have been hunting for on chromosomes 1 and 19. These genes were difficult to find until the technology improved, said Hai Yan, M.D., Ph.D., Duke associate professor of pathology and co-corresponding author of the study.

"The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced," Yan said. "A mutation frequency of 85 percent is very high."

The study was published in the Aug. 4 ahead-of-print issue of the journal Science.

"Whenever we find genes mutated in a majority of tumors, it is likely that the pathway regulated by that gene is critical for the development and biology of the tumor," says Nickolas Papadopoulos, Ph.D., co-corresponding author and associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.

The finding of two additional new genes involved in oligodendrogliomas increases the chances for an effective combination drug therapy for the tumor, Yan said. He envisions a combination cocktail of drugs similar to the combination-drug treatments taken by HIV patients that would target different pathways involved in cancer, and assist in reducing the chance of relapsing, increasing odds of success.

The genes they identified are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments, Yan said.

"Tumor suppressor genes like the ones we found, CIC or FUBP1, won't be targeted directly by small molecules, because the mutated gene products result in loss of function, but the pathways that these genes are involved in could be targeted," Yan said.

"Another very important feature is that the genes could be used as biomarkers to distinguish this type of cancer from other types of brain tumors."

The researchers found CIC on chromosome 19 and FUBP1 on chromosome 1 based on an initial study of seven oligodendrogliomas; they found six mutations and two mutations, respectively, in the seven tumors. Further study of 27 more of these tumors showed that there were 12 and three mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes.

These tumors also contained a glioma (brain tumor) gene mutation identified earlier by Yan and colleagues, the IDH mutations.


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Brazils health care system vastly expands coverage, but universality, equity remain elusive
2. New Research Uncovers Elusive Target of Antifungal Agent
3. Scientists identify order of mutations that lead to cancer
4. Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment
5. P7 protein resistance mutations identified; represent drug targets for hepatitis C virus
6. Study identifies genetic mutations associated with cancer risk for hereditary cancer syndrome
7. Matching targeted therapies to tumors specific gene mutations key to personalized cancer treatment
8. Tracking Swine Flu Virus in Pigs Reveals Mutations
9. Sporadic mutations identified in children with autism spectrum disorders
10. Scientists Spot Key Gene Mutations in Melanoma
11. Ovarian Cancer Prognosis May Depend on Gene Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February ... ... to correct pelvic organ prolapse with the latest techniques and the most minimally ... risk for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR ... AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is ... 5000 perioperative nurses in attendance to study the latest evidence-based recommendations and ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ... indicated by the table. By manipulating each pixel, LUT's can change each color range ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ("Avista ... Setzer as Chief Financial Officer (CFO). Mr. Setzer is ... of experience in various roles within growing technology and ... served as the Executive Director of Finance at INC ... Raleigh, NC . Previously, Mr. Setzer served ...
Breaking Medicine Technology: